Results 151 to 160 of about 7,128 (244)

Janus Kinases Affect Thrombopoietin Receptor Cell Surface Localization and Stability [PDF]

, 2005
Yohan Royer, Judith Staerk, Marcel Costuleanu, Pierre J. Courtoy, Stefan N. Constantinescu   +4 more
openalex   +1 more source

485 In the presence of a PFO, a paradoxical embolism triggered by hormone replacement therapy and Janus Kinase inhibitor

Akeem Yusuf, M Hamaad, A Aslanian, Sherif Mohamed, Sonia Yaqub, Duc-Huy T. Nguyen, John Walker   +6 more
openalex   +1 more source

Janus Kinase Family [PDF]

, 2020
openaire   +1 more source

Intramolecular regulation of Janus kinases

, 2017
Janus-kinaasit (JAKit) ovat ei-reseptorisia tyrosiinikinaaseja, jotka välittävät yli 60 sytokiinin viestejä soluissa. Nämä viestit säätelevät lukuisia biologisia tapahtumia, kuten immuunijärjestelmän toimintaa, hematopoieesia, aineenvaihduntaa sekä kehitystä.
openaire   +2 more sources

Janus-family tyrosine kinase

Citation: 'Janus-family tyrosine kinase' in the IUPAC Compendium of Chemical Terminology, 5th ed.; International Union of Pure and Applied Chemistry; 2025. Online version 5.0.0, 2025. 10.1351/goldbook.13352 • License: The IUPAC Gold Book is licensed under Creative Commons Attribution-ShareAlike CC BY-SA 4.0 International for individual ...
openaire   +1 more source

Hypomethylating agents in vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review

British Journal of Haematology, EarlyView.
Summary VEXAS syndrome (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) is an X‐linked, systemic, haemato‐inflammatory syndrome caused by somatic mutations in the UBA1 gene. No standardized treatment guidelines exist, but evidence is emerging that treatment with hypomethylating agents (HMAs) can induce improvement of the inflammatory symptoms,
Fieke W. Hoff, Roochi Trikha, Emma M. Groarke, Bhavisha A. Patel   +3 more
wiley   +1 more source

Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo [PDF]

, 2020
Shanthi Narla, Sandra Oska, Alexis B. Lyons, Henry W. Lim, Iltefat Hamzavi   +4 more
openalex   +1 more source

Janus kinase (JAK) [PDF]

Science-Business eXchange, 2014
openaire   +1 more source

Targeting MCL‐1 and MAPK overcomes venetoclax resistance in FLT3‐ITD‐positive AML cells harbouring activating PTPN11 (SHP‐2) mutations

British Journal of Haematology, EarlyView.
Summary Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients ...
Maximilian Fleischmann, Ole Hansen, Diana Voigtländer, Julia Bechwar, Lenny‐Joseph Schwietzer, Sanja Bahr, Ulf Schnetzke, Mike Fischer, Florian H. Heidel, Tina M. Schnöder, Jörg P. Müller, Andreas Hochhaus, Sebastian Scholl   +12 more
wiley   +1 more source

P190 An international modified Delphi study to understand clinical opinion on current and potential future use of Janus kinase inhibitors in rheumatic and musculoskeletal diseases: global results [PDF]

Anna Barkaway, Philip J. Mease, Robert J. Moots, Mwidimi Ndosi, Zoe Rutter‐Locher, Michael McLean   +5 more
openalex   +1 more source